Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension

M. R. Grübler, M. Gaksch, K. Kienreich, N. D. Verheyen, J. Schmid, C. Müllner, G. Richtig, H. Scharnagl, C. Trummer, V. Schwetz, A. Meinitzer, B. Pieske, W. März, A. Tomaschitz, S. Pilz

Research output: Contribution to journalArticleAcademicpeer-review


Background and aims Accumulating evidence has proposed a correlation between vitamin D (25(OH)D) insufficiency and cardiovascular (CV) disease. Vitamin D associated effects on endothelial function have been suggested to be a possible culprit. The present study investigated the association of vitamin D3 treatment on markers of endothelial dysfunction in patients with arterial hypertension. Methods and results The Styrian Vitamin D Hypertension Trial is a double-blind, placebo-controlled, single-centre study conducted at the Medical University of Graz, Austria. A total of 200 study participants with arterial hypertension and 25(OH)D levels below 30 ng/mL were enrolled. The study participants were randomized to receive 2800 IU of vitamin D3 per day as oily drops (n = 100) or placebo (n = 100) for a duration of eight weeks. The present study uses an analysis of covariance (ANCOVA) to investigate the effect of vitamin D3 treatment on symmetric (SDMA) and asymmetric dimethylarginine (ADMA). A total of 187 participants (mean [SD] age 60.0 [11.3] years; 47% women; 25(OH)D 21.2 [5.6] ng/mL; mean systolic blood pressure of 131.4 [8.9] mmHg on a median of 2 antihypertensive drugs) completed the trial. Mean treatment effect was −0.004 (95%CI [−0.03 to 0.04]; P = 0.819) on ADMA and 0.001 (95%CI [−0.05 to 0.05]; P = 0.850) on SDMA. In the subgroup analysis patients with a 25(OH)D concentration <20 ng/mL had a significant increase in their log L-arginine/ADMA ratio (mean treatment effect 18.4 95%CI [1.84–34.9]μmol/L/μmol/L; P = 0.030). ClinicalTrials.gov Identifier: NCT02136771 EudraCT number: 2009-018125-70 Conclusions Vitamin D3 supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on ADMA and SDMA.
Original languageEnglish
Pages (from-to)157-163
JournalJournal of Steroid Biochemistry and Molecular Biology
Publication statusPublished - 2018

Cite this